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prevention of major adverse and cardiovas-
cular events in older people. The research
questions tackle areas of major public health
importance.1 The rationale for the conduct
of ASPREE and its protocol have been pub-
lished elsewhere.2,3
To ensure that the proposed trial is rele-
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Aim:  To determine the feasibility of performing a large clinical trial of the use of aspirin 
for the primary prevention of cardiovascular disease in older participants — the ASPirin 
in Reducing Events in the Elderly (ASPREE) trial.
Design and participants:  A randomised double-blind placebo-controlled pilot trial 
of 100 mg of enteric-coated aspirin tablets daily, in men and women aged 70 years 
and over who did not have overt cardiovascular disease, and who were followed for 
12 months. Participants were identified from the computer databases of general 
practitioners who were co-investigators in a previous trial.
ng:  The Melbourne metropolitan area between March 2003 and June 2005.
 outcome measures:  The level of response to participation by GPs; the level of 
nse from potential trial participants; the screening-to-randomisation rate to ensure 
ecruitment target could be achieved; and the retention of participants in the trial 
 12 months.
lts:  Forty-two GPs (23% of 180 mailed) expressed interest in participating in the 
 trial. Nineteen became co-investigators, of whom six were not required to meet 
recruitment targets. Letters were sent to 2614 patients, of whom 243 were screened and 
209 (86%) were randomly allocated to receive aspirin or placebo. At 12 months,192 (92%) 
returned for follow-up, and 153 of these (80%) were still taking trial medication. There 
was a significant reduction in mean haemoglobin level in those taking aspirin.
Conclusions:  The recruitment strategy for ASPREE, based on methods developed 
for the conduct of a previous large-scale trial conducted in general practice, was 
successfully redeployed in this pilot study, with improved efficiency resulting from 
computerised database searching, telephone pre-screening, a simpler run-in phase 
and participant familiarity with the trial drug. We conclude that conducting ASPREE 
in Australian general practice with 18 000 participants is feasible.
Trial registration:  International Standard Randomised Controlled Trial Number 
MJA 2008; 189: 105–109
Register ISRCTN83772183.he
the
cuT  recommended use of aspirin for primary prevention of cardiovas-lar disease is based on absolute
cardiovascular event risk. Age is the greatest
determinant of absolute risk, and yet few
participants in major primary prevention
trials have been elderly. ASPirin in Reducing
Events in the Elderly (ASPREE) is a double-
blind, randomised, placebo-controlled
study of low-dose aspirin for the primary
vant to the current community-based man-
agement of cardiovascular risk in older
people, it will be carried out within general
practice in Australia. To address the issues
identified above, we have proposed a large-
scale trial involving about 18000 partici-
pants aged 70 years and over to determine
the risks versus the benefits of low-dose
aspirin. Here, we present the results of a
feasibility study for the larger trial. The
feasibility study was conducted between
March 2003 and June 2005 in the Mel-
bourne metropolitan area. The key indica-
tors for feasibility for such a large general-
practice-based trial were: (i) the level of
response to participation by general practi-
tioners; (ii) the level of response from poten-
tial trial participants; (iii) the screening-to-
randomisation rate to ensure the recruit-
ment target could be achieved; and (iv) the
retention of participants in the trial after 12
months.
METHODS
General practitioner recruitment
GP co-investigators were purposefully sampled
from those who had participated in the
Second Australian National Blood Pressure
Study (ANBP2) in Melbourne.4 GPs were
excluded if they did not have Medical Direc-
tor clinical software (Health Communica-
tions Network, Sydney, NSW), as research
nurses were trained to prescreen practice
databases by participant inclusion and
exclusion criteria on this clinical software.
GPs vetted these databases to exclude
deceased patients and those they considered
unsuitable or not their usual patients.
Participant recruitment
Volunteers were recruited by a single mail-
out of a letter requesting them to call the
clinical trials centre on a toll-free telephone
number. During this call, patients were
screened further and, if eligible and willing,
an appointment was made for a study entry
visit at their usual general practice clinic by
study staff. At this visit, inclusion and exclu-
sion criteria were checked again by a
research nurse, and participants were
entered into the 4-week placebo run-in
phase. During this phase, an appointment to
discuss the trial with their GP was also
arranged. Following the 4-week run-in
period, eligible participants who were com-
pliant in the run-in phase and who were still
willing to enter the main trial were accepted
and randomly allocated (by an interactive
voice randomisation system, stratified by
practice and age band [70–79 years andMJA • Volume 189 Number 2 • 21 July 2008 105
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(100 mg enteric-coated, daily).
Baseline measurements
Baseline measurements included demo-
graphic data, family and medical history,
concomitant medications, and lifestyle risk
factors such as smoking history, alcohol
use, and physical activity. Blood pressure,
height and weight were recorded. Stand-
ardised questionnaires were administered:
the Geriatric Depression Scale (GDS), the
Medical Outcomes Study 36-item short
form survey (MOS SF-36), the Instrumen-
tal Activities of Daily Living (IADL) scale,
the Modified Mini-Mental State (3MS)
examination and the Color Trails Test. A
biochemical screen at GPs’ routine patho-
logy service providers included measure-
ment of fasting lipid, haemoglobin,
glucose, and serum creatinine levels.
12-month follow-up
Determinations at 12 months after ran-
domisation included compliance checking
by pill count, blood pressure measurement,
reassessment of behavioural traits, neuro-
psychological and quality-of-life tests, and
biochemical markers. Adverse events were
determined by patient and investigator
report, a search of the medical record held
by the practice, and further tracing of data
to source documents in specialist and hos-
pital records.
Endpoints
The primary endpoints of the pilot study
were fatal and non-fatal stroke and cor-
onary events. Secondary endpoints
included dementia and clinically signifi-
cant bleeding (haemorrhagic stroke or
gastrointestinal bleeding requiring trans-
fusion or hospitalisation).
Ethical approval
ASPREE was granted ethical approval by the
Monash University Standing Committee for
Ethics in Research Involving Humans
(2002/278) and the Ethics Committee of the
Royal Australian College of General Practi-
tioners (NREEC 02/22). ASPREE’s trial regis-
try number is ISRCTN83772183.
Data analysis
Differences between groups were analysed
by one-way analysis of variance. Data were
analysed for change over time using paired t
tests comparing values within groups at
baseline and at 12 months. Haemoglobin
levels were analysed by multivariate analysis
of covariance (ANCOVA). A two-sided P
value of < 0.05 was considered significant.
1 Flow chart of screening and 
random allocation of participants 
for the ASPirin in Reducing Events 
in the Elderly pilot study
Figures in square parentheses are projected 
numbers for the main study. ◆
Records reviewed
13 258
[669 275]
Excluded on pre-screening
5487 (41%)
(3607 on aspirin or 
other anticoagulant)
Mail-out database
7771 (59%)
Letters not sent because
recruitment completed
5157 (66%)
Letters sent
2614 (34%)
[225 130]
No response
2024 (77%)
Telephone enquiries
590 (23%)
[50 814] Excluded or did not attend
347 (59%)
[29 885]
Screening visits
243 (41%)
[20 928] Not randomised
34 (14%)
[2928]
Randomised
209 (86%)
[18 000]
2 Pre-screening for exclusion criteria 
on general practice computer 
databases
No. of 
patients
Total patient records reviewed 13 258
Patients excluded at pre-
screening on exclusion criteria 
(below)
5 487
Patients excluded at pre-
screening because they were 
taking aspirin or anticoagulants 
3 607
Exclusion criterion
No. of 
reports
Abdominal aortic aneurysm 91
Myocardial infarction 264
Angina 632
Angioplasty (coronary) 50
Aspirin or anticoagulants
Anticoagulant 837
Aspirin 538
Astrix 1298
Cardiprin 229
Cartia 176
Disprin 1
Solprin 738
Coronary artery bypass graft 247
Coronary artery disease 567
Cerebral aneurysm 6
Coronary angiography 18
Dementia 37
Diabetes 1121
Gastric ulcer 107
Heart failure 246
Ischaemic heart disease 42
Peptic ulcer 253
Peripheral artery disease 209
Stroke 231
Transient ischaemic attack 195
3 Baseline characteristics of the 209 
study participants
Characteristic Value
Mean age in years (SD) 76.2 (4.6)
Age
70–74 years 49.8%
75–80 years 31.6%
 80 years 18.7%
Sex
Male 40.7%
Family medical history
None 52.2%
Heart attack 25.4%
Stroke 13.9%
Dementia 4.8%
Heart attack and stroke 2.9%
Heart attack and stroke 
and dementia
1.0%
First language English 93.3%
Years lived in Australia
0–14 2.8
15–29 2.8
30–44 25.0
45–59 50.0
60–74 8.3
 75 11.1
Education
< 9 years 31.6
9–11 years 33.5
12 years 9.1
13–15 years 13.4
16 years 6.2
17–21 years 6.2106 MJA • Volume 189 Number 2 • 21 July 2008
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GP recruitment
Recruitment letters were mailed to 180 GPs,
65 of whom replied (34 yes, 23 no and
eight requesting more information); 21 let-
ters were returned to sender (14 had left the
address, four had retired, two were
deceased, and no reason was specified for
one). Nineteen GPs were enrolled as co-
investigators, of whom six were not
required to meet the participant enrolment
target of 200.
Participant recruitment 
and characteristics
The identification and enrolment of partici-
pants is illustrated in Box 1. The initial step
of using additional search criteria in compu-
terised medical records enabled the exclu-
sion of ineligible patients (Box 2). For
example, 27% of the general practice popu-
lation screened were identified as taking
aspirin or another anticoagulant. Baseline
characteristics of the final 209 participants
are shown in Box 3. In general, this was an
active, healthy group of men and women
aged 70 years and over.
12-month follow-up
The 12-month follow-up was attended by
192 (92%) of the 209 participants, despite
this being the first contact since randomisa-
tion. Most participants (153; 80%) were still
taking trial medication; 63 (33%) reported
stopping trial medication for a period of
more than 2 weeks in the previous 12
months.
Box 4 shows clinical measurements,
neuropsychological testing, and quality-of-
life measurements at baseline and at the 12-
month follow-up visit, both overall and for
participants randomly allocated to receive
aspirin or placebo. After 12 months of treat-
ment, there were significant increases in
systolic and diastolic blood pressures and
GDS scores, and significant reductions in
haemoglobin and blood glucose levels, and
in waist circumference in the aspirin group.
There were no differences between aspirin
and placebo groups in changes from base-
line in the levels of cognitive function or
independent activities. Haemoglobin and
glucose levels were significantly lower
(P <0.05) and blood pressures higher
(P <0.05) in the aspirin-treated participants
compared with the placebo-treated group.
Health behaviour measures at baseline and
at 12 months are shown in Box 5.
Event rates
There were no primary endpoints in the 192
participants during the 12 months. There
were 19 secondary endpoints consisting of
three cases of Alzheimer disease, four can-
cers and 12 hospitalisations unrelated to the
study drug. There was no major bleeding.
DISCUSSION
ASPREE is a planned major clinical trial
based in Australian general practice. Its aim
is to examine the net effects (risks and
benefits) of low-dose aspirin therapy in
apparently healthy older people free of
established vascular disease and dementia,
both of which impose a major and increas-
ing health burden. ASPREE will also be able
4 Clinical measurements, neuropsychological and quality-of-life test scores* at baseline and 12 months, overall and by 
treatment group for the 192 participants who returned for 12-month follow-up
Baseline 12-month follow-up
Parameter Overall Aspirin Placebo Overall Aspirin Placebo
Height (m) 1.64 (0.09)
Weight (kg) 71.6 (13.4) 71.8 (12.9) 71.7 (13.9) 71.0 (13.6) 71.3 (13.4) 70.8† (13.8)
Waist circumference (cm) 89.3 (12.1) 89.9 (11.5) 89.2 (12.6) 87.9 (12.1) 87.9† (11.8) 87.9† (12.5)
Systolic blood pressure (mmHg) 142.3 (17.3) 141.3 (18.5) 142.2 (16.0) 145.9 (20.7) 147.5† (23.1) 144.3 (17.8)
Diastolic blood pressure (mmHg) 78.0 (9.4) 77.2 (9.4) 78.3 (9.2) 79.5 (10.9) 80.0† (11.1) 79.0 (10.8)
Total cholesterol (mmol/L) 5.6 (1.0) 5.6 (1.0) 5.6 (0.9) 5.5 (0.9) 5.5 (1.0) 5.4† (0.9)
LDL cholesterol (mmol/L) 3.2 (0.8) 3.3 (0.9) 3.3 (0.8) 3.2 (0.9) 3.2 (0.9) 3.1 (0.9)
HDL cholesterol (mmol/L) 1.7 (0.4) 1.7 (0.4) 1.7 (0.4) 1.6 (0.4) 1.6 (0.4) 1.6 (0.4)
Triglycerides (mmol/L) 1.4 (0.7) 1.4 (0.6) 1.4 (0.7) 1.4 (0.6) 1.4 (0.5) 1.4 (0.6)
Haemoglobin (g/L) 139.7 (12.7) 138.9 (12.6) 140.8 (12.4) 139.0 (14.1) 136.5† (14.4) 141.5 (13.4)
Glucose (mmol/L) 5.1 (0.6) 5.1 (0.8) 5.1 (0.5) 5.0 (0.5) 4.9† (0.6) 5.0 (0.5)
Creatinine (mmol/L) 0.08 (0.02) 0.1 (0.02) 0.1 (0.02) 0.09 (0.02) 0.1 (0.02) 0.1 (0.02)
Median C-reactive protein (IQR) (mg/L) 3.0 (2.9–5.3) 3.0 (2.9–5.6) 3.0 (2.9–5.1) 3.0 (3.0–5.0) 3.8 (3.0–5.0) 3.8 (3.0–5.0)
Scores on:
Geriatric Depression Scale 1.6 (1. 7) 1.7 (1.7) 1.5 (1.6) 2.0 (2.2) 2.1† (2.2) 1.8 (1.9)
Instrumental Activities of Daily Living scale 7.9 (0.4) 7.8 (0.5) 8.0 (0.2) 7.79 (0.60) 7.8 (0.7) 7.8 (0.5)
Short form-36
Physical component summary 48.7 (8.2) 47.9 (7.7) 49.7 (8.4) 48.3 (8.6) 47.8 (8.2) 48.8 (8.9)
Mental component summary 56.1 (7.0) 55.8 (7.7) 56.3 (6.1) 54.9 (8.4) 54.7 (7.9) 55.1 (9.0)
Color Trails Interference Index (Z-score)5 − 0.054 (1.20) − 0.057 (1.36) − 0.051 (1.03) − 0.280 (0.99) − 0.269 (1.01) − 0.290 (0.98)
Modified Mini-Mental State examination 93.1 (6.2) 92.7 (6.3) 93.9 (5.4) 93.3 (6.4) 93.0 (6.0) 93.7 (6.8)
LDL = low-density lipoprotein. HDL = high-density lipoprotein. IQR = interquartile range. Short form-36 = Medical Outcomes Study 36-item short form survey.  
* All values are mean (SD) unless otherwise specified. † Indicates a statistically significant difference between baseline and 12 months within group (P < 0.05). ◆MJA • Volume 189 Number 2 • 21 July 2008 107
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other prevalent conditions of older people,
such as cognitive decline and cancer.
There are a number of important findings
from this pilot study that suggest that con-
ducting an 18 000-participant general-prac-
tice-based study in Australia is feasible.
Firstly, computer-based querying of general
practice records to identify potential study
participants was highly efficient. In our
ASPREE feasibility study, instant identifica-
tion of age-eligible patients and the exclu-
sion of 41% of these by searching for further
exclusion criteria (Box 2) significantly
reduced recruitment costs. In our previous
large-scale general practice initiative
(ANBP2), all databases were generated by
hand, and age was the only criterion on
which letters of invitation were sent.6 Sec-
ondly, the 23% response rate to the letter of
invitation is similar to that reported in
ANBP2, and reflects a willingness of older
people to participate in clinical research.
Finally, and most importantly, 86% of those
who entered the run-in phase were ran-
domly allocated to receive aspirin or pla-
cebo in this ASPREE pilot study. On this
basis, and allowing for lower response rates,
about 30 000 people aged 70 years and
older would need to be entered into the
run-in phase to achieve the recruitment
target in the main trial (Box 1). Given that
53 242 participants entered into the screen-
ing phase of ANBP2 within the 2.5-year
recruitment period, the screening target of
30 000 is highly likely to be achievable
within a 2-year recruitment phase in the
main ASPREE study.
Low-dose aspirin therapy has been
shown to reduce the risk of vascular events
in those with manifest atherosclerotic dis-
ease.7 In primary prevention, athero-
sclerotic events can also be reduced.3,8-13 In
addition, there is increasing evidence of the
potential, as yet unproven, of low-dose
aspirin therapy to reduce the rate of intel-
lectual decline in older people.14-16 How-
ever, part of the benefit of aspirin therapy
may be offset by adverse effects, including
gastrointestinal and intracranial bleeding.
Epidemiological modelling suggests that the
routine use of aspirin in people aged 70
years and over who do not have manifest
disease has an uncertain balance of risk and
benefit, and a trial such as ASPREE is
therefore warranted.17 Because the risks and
benefits have not been established in older
participants, aspirin is not widely used for
primary prevention in Australian general
practice. In our screened population, only
27% of patients were currently taking
aspirin or another anticoagulant (Box 2).
This population estimate needs to be inter-
preted with caution, as it included patients
taking aspirin for both primary and second-
ary prevention, and aspirin is available over
the counter, and hence may not be recorded
consistently in GPs’ records. The use of
aspirin in the community is also likely to
increase, given its cardioprotective effects
and the recent evidence of cardiotoxicity
of other non-selective and selective non-
steroidal anti-inflammatory drugs.18
The 80% compliance level at 12 months
observed in our ASPREE pilot study is
consistent with the 81% at 1 year of those
randomly assigned to receive aspirin in the
United Kingdom general-practice-based
Primary Prevention Project (PPP).13 Experi-
ence from PPP and other primary preven-
tion trials suggests that participants stop
taking trial medication predominantly in
the first year, with relatively low rates of
cessation thereafter. The significant reduc-
tion in haemoglobin level observed in the
active treatment arm of ASPREE was also
found in the Prevention with low-dose
Aspirin of Cardiovascular disease in the
Elderly study.19 Such an outcome may be
trivial in younger, more robust populations,
but is likely to be important in older people
in whom comorbidity is common. For
example, occult blood loss may lead to the
development of cardiac failure.20 Nearly one
in five of the cohort of our ASPREE feasibil-
ity study were aged 80 or more years. While
these numbers will be underpowered for
subgroup analysis by age band, it is likely to
give trends if the benefits and harms are
different in the very old.
The observed significant increase in sys-
tolic blood pressure in the aspirin group
may be explained as an association between
aspirin and hypertension, particularly in
women.21 However, no effect was reported
in our own previous pilot study, in any of
the six main primary prevention trials or
their meta-analyses, or in the Antithrom-
botic Trialists Group secondary prevention
meta-analysis.8-13,22,23
Expert groups have also called for the
conduct of a trial such as ASPREE.24,25 In
December 2003, the United States Food and
Drug Administration (FDA) Cardiovascular
and Renal Advisory Committee voted
against a labelling indication for aspirin that
was based on assessment of absolute risk of
coronary heart disease, for which age is the
major determinant.26 The FDA Committee
called for a trial to provide the evidence for
aspirin use in individuals at moderate
cardiovascular risk.
In conclusion, the conduct of ASPREE
within Australian general practice is feasible.
The study has the potential to enable impor-
tant conclusions to be drawn about healthy
ageing.
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